Please ensure Javascript is enabled for purposes of website accessibility

NN (NNBR) Q1 2019 Earnings Call Transcript

By Motley Fool Transcribing - May 10, 2019 at 10:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NNBR earnings call for the period ending March 31, 2019.

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

NN (NNBR -9.47%)
Q1 2019 Earnings Call
May. 10, 2019, 9:00 a.m. ET


  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Good day, and welcome to the NN, Inc. first-quarter 2019 earnings conference call. Today's conference is being recorded. [Operator instructions] At this time, I would like to turn the conference over to Mr.

Robbie Atkinson. You may begin, sir.

Robbie Atkinson -- Executive Vice President, Life Sciences

Thank you, operator. Good morning, everyone, and thanks for joining us. I'm Robbie Atkinson, executive vice president, and I'd like to welcome you to NN's first-quarter 2019 earnings conference call. Our presenter this morning is President and Chief Executive Officer Rich Holder.

If anyone needs a copy of the press release or the supplemental presentation, please contact Abernathy McGregor at (212) 371-5999, and they'll be happy to send you a copy. Before we begin, I'd ask you that you take note of the cautionary language regarding forward-looking statements contained in today's press release, supplemental presentation and in the Risk Factors section in the company's 10-K for the year ended December 31, 2018. The same language applies to comments made on today's conference call, including the Q&A session as well as the live webcast. Our presentation today will contain forward-looking statements regarding sales, margins, foreign exchange rates, cash flow, tax rate, acquisitions, synergies, future operating results, performance of our worldwide markets and other topics.

These statements should be used with caution and are subject to various risks and uncertainties, many of which are outside of the company's control. The presentation also includes certain non-GAAP measures as defined by SEC rules. A reconciliation of such non-GAAP measures is contained in the tables in the final section of the press release and the supplemental presentation. First, we'll give an update and overview of the first quarter, and Rich will provide commentary on the business.

Then we'll walk you through the numbers and discuss Q2 outlook. Then afterwards, we'll open up the line for questions. With that said, Rich, I'll turn the call over to you.

Rich Holder -- President and Chief Executive Officer

Thanks, Robbie. Good morning, everyone, and welcome to our Q1 2019 conference call. As usual, over the next few minutes, I'll take you through our Q1 results, and then we will open the lines for questions. With that, let's dive into the highlights.

Net sales for the quarter was $213.3 million. Sales growth of $44.1 million, the majority of which was driven by our Life Sciences business. Acquisitions contributed a total of $55.2 million within the quarter to the top line. Adjusted EBITDA of $34.5 million, with operating performance as expected, and I will say that our integrations are all on track and performing as expected.

Adjusted operating margins expanded by 30 basis points over the prior year to 10.8%, led by the improvements by Life Sciences by the growth as well as the synergy capture but also in large part by the appropriate flexing of our Mobile Solutions business in the face of significant market headwinds. Adjusted diluted EPS of $0.20. Free cash flow for Q1 was a usage of cash of $16.8 million, which is -- which actually is slightly better than planned. Let me remind you, as we talk about cash, that we introduced this on the last call, we told you we would move to a standard definition of free cash flow, and so our definition is now operating cash flow minus capex.

So it's right of the face of our financial documents. As we move over to Page 4, again in the net sales column, net sales up $44 million versus prior year. Total acquired sales inclusive of organic growth within the acquisitions was $55 million, offsetting the contraction primarily in our Mobile Solutions business of about $10 million in actual sales. On an adjusted diluted earnings per share, $0.20.

Let me remind you that in the third quarter of 2018, we issued 14.4 million shares, and so you can use that to be appropriate comp. On a gross margin perspective, we were 24.4%. Our margin was offset by continued investment and integration activities. Those activities in total equate to about 150 basis points.

SG&A, acquisitions added $5 million. I think the comp on SG&A begins to be a little bit more realistic as we get further into the year, but SG&A is performing as expected within the business. As we move over to Page 5. Adjusted operating margin of 10.8%, again, an expansion of 30 basis points.

And I have to point out that the Mobile Solutions business flexed in an expected manner and held and in fact increased their margins over and above what we would have expected. Adjusted EBITDA margin of 16.2%. And as we move toward the bottom of the page, if you recall, last quarter, we introduced you to this slide. We wanted to give you a view into our debt leverage position as it relates to our credit agreements.

We had lots of questions around that. So we wanted to be as transparent around that as possible. So as you look at this chart and you compare quarters on a year-over-year basis, you can see the effects on our leverage. Q1 2019 leverage came in a bit better than planned and currently sits at 5.1.

As I'm sure you're aware, our normal seasonality around cash is, we use cash in the first half of the year. We begin to generate cash in the third quarter, and we generate a significant amount of our cash in the fourth quarter. It's a little bit smoother than it was in the years gone by, but our seasonality remains the same. So there's no reason to expect our cash generation profile to change.

As we go into the businesses on Page 6, Life Sciences Group. Let me just take a moment to orient this chart. The red bar represents the performance of the business had we owned all the acquisitions on January 1, 2018. It's intended to allow you to get a very clear view of the organic growth that's occurring inside of the businesses as we put these businesses together.

So as you look at the comparison base -- from a comparison basis, this business is up $12 million or roughly 17% in organic and $55 million from the Q1 actual plus inclusive acquisition. Our integration and synergy plans are on track, and you see the effects of this continuing synergy capture when you look at the comparison in the adjusted operating margins section from 17.4% going up to 20%. Maybe a couple of key points on the Life Sciences business that you want to be aware of. Our backlog continues to grow and currently sits in excess of $200 million.

Our new business pipeline is in the neighborhood of something north of $100 million. So in total, one could argue we have about $300 million sitting in total backlog. And we continue to expand our engineered solutions business as utilizing all our facilities to make product to go into total solution sets that we're selling into the marketplace, which was a significant strategic move versus we put these businesses together. So we feel pretty good about the performance of our Life Sciences business.

As we move onto Page 7, Power Solutions Group. This business, again, underperformed within the quarter. The underperformance was, again, the result of the same customer supply chain disruption that was not abated. I will tell you it does appear now that the issue has been resolved as we're seeing normal shipping volume as of the month of May.

So fundamentally, we may still see some overhang in the second quarter because the volumes didn't get back to normal until May, but we think this issue is largely in our rearview mirror. Sales were fundamentally flat, and you see the operating margin at 16.9%, largely on the back of the new program launches, which are all on track and all now shipping at low rate of production volumes. The ramp-ups are expected to occur the majority in the second half of the year. And in concert with those ramp-ups, you should expect to see the margin of the business begin to return to its normal state.

As we move over to Mobile Solutions, this is sort of the mother of all headwinds. We are all aware what's going on with the global automotive market. This is a very tough comp, I will tell you, because Q1 of 2018 was a record sales quarter for our business. And so we're down some $12 million year over year.

When you think about the makeup of that, $2.5 million of that $12 million is all in FX working against us. Geographically, North America is down about 11%. So we expected that as the markets begin to turn. Europe is down about 2%, and the rest of the world is flat.

So China has leveled off. Certainly Brazil is up a little bit. So the world is sort of selling to about a 93 million unit SAAR rate, which is above what we expected at trough. Our business is flexing appropriately as we begin to and we continue to finish many of our product launches, which occurred in the second half of the year.

We have a significant amount of spending abatement in this business, and we have a sales uptick in this business, and so we expect margins to normalize in this business as we go through the second half of the year. Nonetheless, noteworthy performances in terms of flex from this business. As we go to Page 9, the summary. Again, sales of $21.3 million organic growth across the entire corporation of 1% driven by 17% organic growth in the Life Sciences business and, of course, offset by the contraction in the Mobile Solutions business.

Adjusted EBITDA of $34.5. Adjusted operating margin improvement of 10.8%, and adjusted EPS of $0.20. As we go over to guidance, our guidance for the year has not changed. So I won't really spend any time on this chart.

We'll just go to guidance for the second quarter. As we look up to the second quarter, we think our top line will be between $215 million and $222 million, and we expect EBITDA to come in between $35 million and $40 million. I think with that, we can open the lines for questions.

Questions & Answers:


Thank you very much. [Operator instructions] Our first question will come from Rob Brown, Lake Street Capital Markets.

Rob Brown -- Lake Street Capital Markets -- Analyst

Well, you're right. Nice job on the quarter and good execution in a mixed environment there. Just wanted to touch on Life Sciences. You're seeing good strength there.

What's sort of the operating margin thinking that, that can become and maybe some further clarity on the integration where you're at and the synergies you're starting to see there?

Rich Holder -- President and Chief Executive Officer

Yes. So recognize, as we put this business together, we told you we have kind of a three-year integration plan from -- so from the point in time that we got Paragon, recognize that was Bridgemedica before that, DRT before that. On the other side of all the integration and after all the synergy captures, we think this is sort of a 23% to 25% business. We had this year, overall, we think we should see this business sort of rise to about 21% as we get the synergy capture within this year, and then there's some spillover into next year, and then, of course, there's a full-year effect of the entire synergies.

So when you think about this business in a normal run rate environment, call it 24% to 26% bottom of the cycle and top of the cycle.

Rob Brown -- Lake Street Capital Markets -- Analyst

OK. Great. That's a good business. And then shifting to mobile, I know you're seeing headwinds and you've flexed down.

But are you -- sort of how do you kind of handle this environment? Are you continuing to introduce new products? Or is it a case you've kind of got the product set now ramping and you're just following the market demand and managing your cost structure against that?

Rich Holder -- President and Chief Executive Officer

Yes. So it can release. It's a little bit of both, right? The biggest movement in mobile, as you look toward the balance of the year, is recognize that we have been investing in a significant amount of new programs. We talked about it a lot last year.

And we said that you would see those new programs manifest themselves basically mid- to second half of '19, of this year. And so that is the expectation. We are seeing those programs move out of SOP and things like that and move into full production. Now it's clear that the full production volumes that we had originally anticipated is somewhat muted, but nonetheless, it's full production volume, and so it's offsetting some of the market headwinds as we go forward.

In terms of brand-new programs, I mean, we are always looking at brand-new programs. We are, I think, making wise investment decisions as we look forward to some of the newer programs because you know in this businesses you got to put capital in place 12 to 18 months ahead of production volume. And so we are mindful of what that may or may not do to the business, and so that's certainly a filter. We still believe in this business, and we still think this is a great business to grow.

I think we just have to grow it in an intelligent fashion, and that's kind of the way we're going at it.

Rob Brown -- Lake Street Capital Markets -- Analyst

Great. Thank you I'll turn it over.


Thank you very much. Our next question will come from Mig Dobre, Baird.

Mig Dobre -- Baird -- Analyst

Thank you. Good morning, everyone. A couple of questions for me. I want to start with guidance. When I'm looking at your Q2 guidance, it seems to be below on both revenue and EBITDA from the ranges that you've hinted at or you provided rather with your 2019 preview, talking about last quarter's slide deck, Slide 17, specifically.

So I guess, what I'm kind of scratching my head on is if Q1 was pretty much in line with what you were thinking, so performance here was in line, you're reiterating the year, Q2 is not as robust as you were thinking initially. What changed? And can you maybe provide that commentary at segment level? And how do we makeup for slightly softer than expected Q2?

Rich Holder -- President and Chief Executive Officer

Yes. So I don't think anything has changed. I think we continue to take a prudent look at the year. I think what we said to you was the way to think about our business was, in Q1, we'd see sort of 23% to 25% of our sales.

Q2, we'd see kind of 25% to 27% of our sales. I think we're still holding to that model, as we suggested in the 2019 preview. Candidly, nothing has changed. We performed a little bit better in Q1 than expected.

And so I think we should take a prudent view of the out quarters, and that's what we continue to do.

Mig Dobre -- Baird -- Analyst

Well, I mean, Rich, math is math. If we apply those ranges to the midpoint of your guidance, we end up with a different Q2 than what you're currently guiding to. So I mean, the numbers are what they are. My question is, why is the quarter looking different now than what you originally guided? And I get the fact that nobody has got sort of perfect visibility, but I'm trying to understand exactly what the delta is versus your initial plan.

Rich Holder -- President and Chief Executive Officer

Yes. I will tell you, and we can certainly discuss this in some detail off-line. I will tell you that. At best, the quarter has moved around maybe a point.

So we don't view it as we came off over any number of change in a substantive way. We've not come off the year. We've not come off the time phasing that we thought. And so maybe what we need to do is sit together and work through what you're looking at versus what I'm looking at.

But we're not seeing the substantive change that you seem to be indicating.

Mig Dobre -- Baird -- Analyst

OK. Then, if I may ask this question, it looks to me like your implied EBITDA margin guidance for the second quarter is essentially baking in fairly sizable margin compression, about 130 basis points. We've seen some margin compression in Q1 as well. The back half guidance is implying pretty significant margin expansion.

Can you give us a sense for how you're looking to deliver that? I'm presuming a good chunk of that comes from Life Sciences, but some of the other segments your perspective there would be helpful as well.

Rich Holder -- President and Chief Executive Officer

Yes. So I think you hit on certainly on one of those things, right? So Life Sciences certainly is a more robust business in the latter part of the year. It's just simply seasonality has a lot to do with folks meeting their deductibles and so on and more procedures taking place in the later part of the year. So the Life Sciences business is certainly up H2 over H1.

We're also deeper into synergy capture during that time and so both significantly affect margins. The other thing that happens is there's a significant amount of spending abatement in both Power Solutions and Mobile Solutions business because as Mobile Solutions moves more of these programs into full production, there is a fair amount of spending abatement there, and the same thing happens in power. So that really is the predominance of what drives better margin performance in the second half as well as volume and sales.

Robbie Atkinson -- Executive Vice President, Life Sciences

I would just add one thing, Mig. I'm not exactly sure I followed the comment on -- and Mig, we can again talk about this off-line. But in Q2, the guide for EBITDA would imply the bottom into the range effectively the same margin to a margin that gets about 180 basis points better quarter-over-quarter. So we could talk about that more off-line.

I think we're talking on a couple of hours, but I don't see margin compression.

Mig Dobre -- Baird -- Analyst

Robbie, is your comment year over year or sequential?

Robbie Atkinson -- Executive Vice President, Life Sciences

Sequential. Yes. So I mean, we -- again, we could talk about it. We could talk about it again, off-line.

But I think...

Mig Dobre -- Baird -- Analyst

We can, but I mean -- my point was that on a year-over-year basis, you're expecting margin contraction in the second quarter. On a year-over-year basis in the back half of the year you're expecting pretty significant margin expansion. That's how you get there. So sequential comment, you have to do with seasonality and other items, which right, but year over year, that's really helped probably everybody who's modeling your business.

Rich Holder -- President and Chief Executive Officer

So on a year-over-year basis, the performance of the Mobile Solutions business in the second quarter of '18 versus the second quarter of '19 is substantially different. And so there is definitely contraction in that business on a year-over-year basis, and so that's probably what we are seeing. The other thing is that the business that we had in the second quarter of '18 is not the business we have in the second quarter of '19, right? We didn't have Paragon in there. There's a number of things that we didn't have in there.

We weren't in at pre-integrated state as we are now. So I take your point, but I think we -- we may be comparing apples and oranges.

Mig Dobre -- Baird -- Analyst

Very well. Then I'll ask one last question on leverage. Can you give us a sense for how you think about this number through the year? Where do you see the leverage peak? And it looks to me like on the last call you expect the leverage to peak at about 4.9x. That was in the Q&A discussion.

We're already above that. So how do you think about that? And more importantly, if depending on macro customers whatever, the volume outlook changes as the year progresses. How do you think about managing your leverage as you look into the second half of the year and into 2020 from a risk perspective? Thank you.

Rich Holder -- President and Chief Executive Officer

Yes. So in terms of the year, I think we continue to follow our normal path. As I said, Q1 came in a little bit better than our expectation. I think what you will see is a slight tick up in Q2, as is normal for our business.

And then you'll start to see substantial drop in Q3 and Q4, that is just due to our normal seasonality. That's where we generate the cash. That's just our normal seasonality. We continue to be laser-focused on delevering this business.

We understand the concerns around it. We certainly expect to make a substantive move on this as we get into the end of '19 and into 2020. That is what the organization is certainly focused on. Beyond that, I'm not sure what else I can tell.

Mig Dobre -- Baird -- Analyst

Are you going to provide a view as to where you think your leverage would top off in '19?

Rich Holder -- President and Chief Executive Officer

Yes. So I think -- I don't have a number in front of me, but I would tell you it's probably will top off slightly up from where it is today in Q2 and then begin to come down and if you look at the chart and you go back to Q2 of last year sort of the same run rate. And a lot of that has to do with building working capital and other things that then gets relieved in the second half of the year and generate cash. So the profile of the business hasn't changed substantially.

It's a little smoother, but it hasn't changed substantially.

Mig Dobre -- Baird -- Analyst

OK. Thank you.


Thank you very much. Our next question will come from Steve Barger, KeyBanc Capital Markets.

Steve Barger -- KeyBanc Capital Markets -- Analyst

Hey. Good morning, guys. Rich, on mobile, if I heard you right, you said North America was down 11%, which is quite a bit deeper than what we heard for overall auto production in the quarter. Are you on a specific program that declined? Or anymore detail around what's going on there?

Rich Holder -- President and Chief Executive Officer

Yes, I think for us, it had as much to do with program timing as anything else. If you recall, there were a couple of quarters that we weren't down as bad as the market was and now essentially what this is sort of our catch up, right? We hadn't seen this level of degradation in North America prior to this in part because we were on late-cycle programs. But now those programs are coming to an end, the new programs are coming in. So there's about a month or two delta to offset.

So that's why we're at 11%.

Steve Barger -- KeyBanc Capital Markets -- Analyst

Gotcha. And from a modeling perspective, maybe you said this and I missed it, we should expect negative growth in 2Q as well. And just to confirm, you still expect positive growth for the year?

Rich Holder -- President and Chief Executive Officer

Yes. We still think positive for the year roughly somewhere between 1% and 2%. We're not talking massive growth. But yes, we're still holding that for the year at this point.

Steve Barger -- KeyBanc Capital Markets -- Analyst

But down in 2Q.

Rich Holder -- President and Chief Executive Officer

Yes, we think a little bit down in Q2.

Steve Barger -- KeyBanc Capital Markets -- Analyst

One of the focus points has been growing the industrial business to offset some of this global auto exposure. Can you talk about progress there and maybe talk about how you view the size of the market -- the realistic size of the market opportunity in your circle of confidence?

Rich Holder -- President and Chief Executive Officer

Yes. I will tell you that we've been working pretty diligently in trying to grow that piece of the business. We have had some success. We have recently won a significant new program that we'll be going into one of our Mexico facilities.

It's not going as quickly as I think -- as we'd like it, and I think we're in the process of looking at this and see as if we can sort of redouble our efforts around that space. I think trying to put sort of a ball around the market size in this space is a little tough, but I'll tell you the market that we are of looking at and we can play in is easily sort of a $50 billion to $70 billion sort of market across the entire globe. Part of what we are trying to make sure that we do is maintain our focus on growing the wallet share of the customers that we already have and not running out and having to establish brand-new relationships. So most of our program focus is on customers, some of the diversified industrial customers that we have today that have general industrial segments that we can have one large customer relationship.

It's probably the best way to think about it.

Steve Barger -- KeyBanc Capital Markets -- Analyst

Yes. How are you balancing prospecting in that process between medical and industrial? Is there a limitation in terms of sales and engineering? Or do you -- are you capacitized enough to go in multiple directions right now?

Rich Holder -- President and Chief Executive Officer

So with respect to the general industrial segment, we are capacitized to go in multiple places. We don't -- we sort of don't allow that to crossover into the Life Sciences side of it. There is, for lack of a better phrase, the Chinese Wall between the two. So there are no limitations in terms of prospects for Life Sciences at this stage of the game at all.

Steve Barger -- KeyBanc Capital Markets -- Analyst

And -- OK. Last one for me. When you think about the free cash flow characteristics of the segments, as Life Sciences becomes a bigger part of the portfolio, shouldn't it help balance cash generation through the year? Or does it have the same use in the first half stores in the back half kind of pattern?

Rich Holder -- President and Chief Executive Officer

Yes. So it should smooth the generation a bit, but recognize they still have very much a second half -- sort of mid-year to second half bet, right? And that has directly to do, again, what I said earlier, there are more procedures taking place in the second half of the other than the first half of the year. So generally, there are inventory bill, there are inventory positioning, there's a lot of dollars, if you will, spent in the first half of the year that kind of all find their way through the cycle and the second half of the year. And it's directly related to when people meet their deductibles on the medical plan.

Steve Barger -- KeyBanc Capital Markets -- Analyst

Right. All right. Thank you.


Thank you very much. [Operator instructions] Our next question will come from Daniel Moore, CJS Securities.

Daniel Moore -- CJS Securities -- Analyst

Good morning. Thanks, Rich. Maybe in Power Solutions, Rich, it sounds like you're confident that the customer supply chain issues are in the rearview mirror. Can we possibly quantify the impact on Q1 revenue and operating income in the segment? And any detail in terms of progress, and what gives you confidence that we are behind that?

Rich Holder -- President and Chief Executive Officer

Yes. So round numbers in the quarter, and I say round numbers, about $2 million. The confidence that we have, number one, the customer is telling us that they think this problem has been abated. But maybe more importantly, the way we build this product is we receive dunnage from the customer, and so we bill to the dunnage.

It's adjusting time line. So we built to the dunnage and ship to the customer. So if the customer has any level of disruption or they need to balance inventory or anything in any way shape or form, what they do is they restrict the amount of dunnage that they send to us. So there's only so much can bill, right? So in this particular case, we couldn't even build inventory if we wanted to.

Because the -- where the product fit, it has to fit in the dunnage. And so what gives us the confidence back there that this is abated is the fact that we are getting dunnage that is at or beyond our normal shipping levels in the month of May. We did not get that in April, but we have been getting that in the month of May, and there appears to be a small, I say, a modicum move of catch up, if you will, if you look at the dunnage, but we'll see how that plays for the rest of the month.

Daniel Moore -- CJS Securities -- Analyst

Helpful. And switching over to Mobile Solutions, maybe just drill down a little in terms of free cash flow within the segments. In the past, you've kind of described it in as typical downturns, you would work down working capital that would reverse and you see free cash flow benefit. Wondering if you're seeing that in the first half of the year or this year recognizing you've got some as you expand platforms, but are you seeing that what you would normally expect as far as that goes?

Rich Holder -- President and Chief Executive Officer

Yes. So I think we've seen a bit of improvement, certainly in the quarter. And I think it speaks to the decremental performance certainly. But recognize we have programs that we're launching in the middle of the year.

So we are not in sort of sky's falling mode in that business, right? We're still talking about a business that is largely flat to a 1% to 2% growth in the business. So we are not, for lack of a better word, in harvest mode like we would have been in sort of 2007, 2008, right? We're still investing in the business. We're still running the business. We're still looking to grow the businesses, and it's still a sort of tough quartile business in its space.

Daniel Moore -- CJS Securities -- Analyst

OK. Helpful. And then one last one maybe drilling down on the synergies that are expected. Maybe just update us on where we are in terms of the overall synergies expected to be captured in Life Sciences.

What's embedded in the 2019 guide? How much is left for 2020 and beyond? Thanks.

Robbie Atkinson -- Executive Vice President, Life Sciences

Yes. So Dan, good question. If you look at where we are in relation to our synergy plan, I think you have to step back a little back from Paragon and look at the entire business. And as you pull it together, you have room in the Life Sciences segment as 15 months old.

And so you have the integration there, you have integration of Paragon pulling that together. And then you have DRT and Bridgemedica as well, all in there. And so when you look at it, the good news is we're on track, right? So we're able to look at the synergy plan that we had and where we are in terms of what we expected to be delivering from an operating profit dollars perspective, and we're right where we expect it to be. I think we still have room to go in terms of operating efficiency.

We're not saying bingo yet in terms of that we got all the way there, but we are at a place were we're really starting to see those synergies come through. I think you saw that in the first-quarter performance and the step-up from Q4 margin. So we're excited about that and we think as you look out throughout the year. You'll continue to see margin expansion in the business, driven really in large part by synergies and continuous improvement within the entire segment as we pull that entire business together.

And then certainly, we would expect margins to continue to expand as we move toward that strategic target of 24% to 26%.

Daniel Moore -- CJS Securities -- Analyst

OK. And in terms of dollars on a run rate basis, not possible to quantify sort of what remains beyond '19 or just continued improvement of the -- that we should think about?

Robbie Atkinson -- Executive Vice President, Life Sciences

I think we laid out a three-year $30 million synergy plan, and it's not the second year or the largest year in that. So it's not a sequential $10 million, $10 million, $10 million. We didn't give granular guidance. So we've not given granular guidance on how the synergies specifically lay in over that period.

But you should think of it probably like a bell curve. Synergies tend to take a moment to ramp up, because you don't want to make too many changes at first. And then you tend to get sort of peak synergy activity in year 2, and then they start to wind down in year 3.

Daniel Moore -- CJS Securities -- Analyst

Thank you.


Thank you very much. At this time, we have no further questions in the queue. So I'd like to turn this conference back over to management for closing remarks.

Rich Holder -- President and Chief Executive Officer

Thank you, operator. Thank you all for joining us on this call, and we will chat with you next quarter. Thank you.


[Operator signoff]

Duration: 37 minutes

Call participants:

Robbie Atkinson -- Executive Vice President, Life Sciences

Rich Holder -- President and Chief Executive Officer

Rob Brown -- Lake Street Capital Markets -- Analyst

Mig Dobre -- Baird -- Analyst

Steve Barger -- KeyBanc Capital Markets -- Analyst

Daniel Moore -- CJS Securities -- Analyst

More NNBR analysis

All earnings call transcripts

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NN, Inc. Stock Quote
NN, Inc.
$2.58 (-9.47%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.